Advancements in the Management of R/R AML: ASH 2024 - Episode 5

Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

January 22, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

Now Viewing

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

EP. 10: Emerging Combination Strategies and Preclinical Findings

EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias

EP. 12: Closing Perspectives on R/R AML Treatment Advances

Video content above is prompted by the following:

Briefly comment on data updates presented for the AUGMENT-101 trial.
Given the 64% ORR and 23% CR/CRh rate observed with revumenib in patients with heavily preated pretreated KMT2A-rearranged acute leukemia patients, how do you see this therapy reshaping the treatment landscape for this high-risk population?
Briefly comment on the clinical implications, particularly in the context of bridging to stem cell transplantation.?